%0 Journal Article
%T Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date
%A Am¨Ślie Boespflug
%A Julie Caramel
%A Luc Thomas
%A Stephane Dalle
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2017
%R 10.1177/1758834017708160
%X The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15¨C25% of all metastatic melanoma patients. It currently does not have an approved targeted therapy. Metastatic patients receive immune-based therapies as first-line treatments, then cytotoxic chemotherapy like carboplatin/paclitaxel (C/P), dacarbazine (DTIC) or temozolomide (TMZ) as a second-line treatment. We will review current preclinical and clinical developments in NRAS-mutated melanoma, and analyze ongoing clinical trials that are evaluating the benefit of different targeted and immune-based therapies, either tested as single agents or in combination, in NRAS-mutant melanoma
%K NRAS-mutant melanoma
%K targeted therapies
%K metastatic melanoma
%K clinical trials
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502949/